FDA Approves NEFFY — ARS Pharmaceuticals Operations, Inc.

# FDA Approves ARS Pharmaceuticals' NEFFY, First Nasal Epinephrine Auto-Injector Alternative ARS Pharmaceuticals Operations, Inc. received FDA approval for NEFFY (epinephrine nasal spray) on August 9, 2024, marking a significant market entry in the emergency allergy treatment space and positioning the company to capture share from the dominant auto-injector market currently led by EpiPen. The nasal delivery mechanism offers a potential competitive advantage by eliminating the need for intramuscular injection, which could appeal to patients and caregi